4D Molecular Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
4D Molecular Therapeutics, Inc. (FDMT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $24.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2025-02-28
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $24.00M, a 31.15% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $18.30M, a 21.19% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $15.10M, a 9.42% increase from fiscal 2021.
- 4D Molecular Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2021 was $13.80M, a 176.00% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|
| 2024-12-31 | $24.00M 10-K · filed 2025-02-28 |
| 2023-12-31 | $18.30M 10-K · filed 2025-02-28 |
| 2022-12-31 | $15.10M 10-K · filed 2024-02-29 |
| 2021-12-31 | $13.80M 10-K · filed 2023-03-15 |
| 2020-12-31 | $5.00M 10-K · filed 2022-03-28 |
| 2019-12-31 | $2.20M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |